Nurix Therapeutics (NRIX) Projected to Post Earnings on Thursday

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) is expected to post its quarterly earnings results on Thursday, February 20th. Analysts expect Nurix Therapeutics to post earnings of ($0.67) per share for the quarter.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Trading Up 0.1 %

NRIX stock traded up $0.02 on Friday, hitting $17.59. The company's stock had a trading volume of 663,752 shares, compared to its average volume of 662,863. The firm has a 50 day moving average of $19.43 and a two-hundred day moving average of $22.14. Nurix Therapeutics has a 1 year low of $9.22 and a 1 year high of $29.56. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -6.09 and a beta of 2.14.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Royal Bank of Canada boosted their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. Needham & Company LLC dropped their price objective on shares of Nurix Therapeutics from $29.00 to $28.00 and set a "buy" rating on the stock in a research note on Wednesday, January 29th. BMO Capital Markets started coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They issued an "outperform" rating and a $35.00 price objective on the stock. JPMorgan Chase & Co. lowered their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Finally, Morgan Stanley upped their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research note on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $31.12.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,811 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $55,798.35. Following the transaction, the chief financial officer now directly owns 39,549 shares in the company, valued at approximately $785,047.65. This represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gwenn Hansen sold 3,690 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.20% of the stock is owned by corporate insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.